181 related articles for article (PubMed ID: 9806487)
1. L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350).
Robinson WE
Antiviral Res; 1998 Aug; 39(2):101-11. PubMed ID: 9806487
[TBL] [Abstract][Full Text] [Related]
2. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1.
Beale KK; Robinson WE
Antiviral Res; 2000 Jun; 46(3):223-32. PubMed ID: 10867160
[TBL] [Abstract][Full Text] [Related]
3. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase.
King PJ; Robinson WE
J Virol; 1998 Oct; 72(10):8420-4. PubMed ID: 9733896
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.
Lee DJ; Robinson WE
J Virol; 2004 Jun; 78(11):5835-47. PubMed ID: 15140981
[TBL] [Abstract][Full Text] [Related]
5. Chicoric acid analogues as HIV-1 integrase inhibitors.
Lin Z; Neamati N; Zhao H; Kiryu Y; Turpin JA; Aberham C; Strebel K; Kohn K; Witvrouw M; Pannecouque C; Debyser Z; De Clercq E; Rice WG; Pommier Y; Burke TR
J Med Chem; 1999 Apr; 42(8):1401-14. PubMed ID: 10212126
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
King PJ; Ma G; Miao W; Jia Q; McDougall BR; Reinecke MG; Cornell C; Kuan J; Kim TR; Robinson WE
J Med Chem; 1999 Feb; 42(3):497-509. PubMed ID: 9986720
[TBL] [Abstract][Full Text] [Related]
7. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
8. Caffeoylglycolic and caffeoylamino acid derivatives, halfmers of L-chicoric acid, as new HIV-1 integrase inhibitors.
Lee SU; Shin CG; Lee CK; Lee YS
Eur J Med Chem; 2007 Oct; 42(10):1309-15. PubMed ID: 17434650
[TBL] [Abstract][Full Text] [Related]
9. New developments in anti-HIV chemotherapy.
De Clercq E
Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.
Johnson AA; Marchand C; Pommier Y
Curr Top Med Chem; 2004; 4(10):1059-77. PubMed ID: 15193139
[TBL] [Abstract][Full Text] [Related]
12. L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro.
Reinke RA; Lee DJ; McDougall BR; King PJ; Victoria J; Mao Y; Lei X; Reinecke MG; Robinson WE
Virology; 2004 Sep; 326(2):203-19. PubMed ID: 15302207
[TBL] [Abstract][Full Text] [Related]
13. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
Pluymers W; Neamati N; Pannecouque C; Fikkert V; Marchand C; Burke TR; Pommier Y; Schols D; De Clercq E; Debyser Z; Witvrouw M
Mol Pharmacol; 2000 Sep; 58(3):641-8. PubMed ID: 10953059
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
Okamoto M; Okamoto T; Baba M
Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of triterpene-azidothymidine conjugates on proliferation of human immunodeficiency virus type 1 and its protease.
Ma CM; Nakamura N; Hattori M; Kawahata T; Otake T
Chem Pharm Bull (Tokyo); 2002 Jun; 50(6):877-80. PubMed ID: 12045355
[TBL] [Abstract][Full Text] [Related]
16. Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations.
Reinke RA; King PJ; Victoria JG; McDougall BR; Ma G; Mao Y; Reinecke MG; Robinson WE
J Med Chem; 2002 Aug; 45(17):3669-83. PubMed ID: 12166940
[TBL] [Abstract][Full Text] [Related]
17. In search of authentic inhibitors of HIV-1 integration.
Debyser Z; Cherepanov P; Van Maele B; De Clercq E; Witvrouw M
Antivir Chem Chemother; 2002 Jan; 13(1):1-15. PubMed ID: 12180645
[TBL] [Abstract][Full Text] [Related]
18. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
19. Catechol-substituted L-chicoric acid analogues as HIV integrase inhibitors.
Lee JY; Yoon KJ; Lee YS
Bioorg Med Chem Lett; 2003 Dec; 13(24):4331-4. PubMed ID: 14643320
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.
King PJ; Lee DJ; Reinke RA; Victoria JG; Beale K; Robinson WE
Virology; 2003 Feb; 306(1):147-61. PubMed ID: 12620807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
